Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Operating activities:    
Net income (loss) $ (19,165,000) $ 4,357,000
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation 88,000 107,000
Deferred income taxes 52,000  
Stock based compensation $ 1,311,000 20,000
Fair value of warrant liabilities in excess of proceeds from financing   946,000
Change in fair value of derivative liabilities $ 11,528,000 (7,744,000)
Realized loss (gain) on marketable securities $ 1,685,000 (480,000)
Loss on sale of equipment   2,000
Changes in operating assets and liabilities, net of effects of reverse Merger with Biozone Pharmaceuticals, Inc. and the merger with RFS Pharma, LLC:    
Prepaid expenses and other current assets $ (115,000) (14,000)
Accounts payable and accrued expenses 526,000 (312,000)
Net cash used in operating activities $ (4,090,000) (3,118,000)
Investing activities:    
Cash acquired in reverse merger with Biozone Pharmaceuticals, Inc.   $ 589,000
Purchase of fixed assets $ (18,000)  
Long term deposits   $ (12,000)
Proceeds from sale of marketable securities   5,400,000
Investment in mortgage note receivable   $ (2,626,000)
Principal payments received on mortgage notes receivable $ 37,000  
Net cash provided by investing activities 19,000 $ 3,351,000
Financing activities    
Proceeds from exercise of stock options 20,000 57,000
Proceeds from issuance of common stock and warrants 15,862,000 2,750,000
Net cash provided by financing activities 15,882,000 2,807,000
Net increase in cash and cash equivalents 11,811,000 3,040,000
Cash and cash equivalents at beginning of period 3,970,000 1,034,000
Cash and cash equivalents at end of period 15,781,000 4,074,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Unrealized gain (loss) on marketable securities net of tax (236,000) $ 1,827,000
Estimated fair value of warrants exchanged for common shares $ 13,862,000  
Assets acquired and liabilities assumed in reverse Merger with Biozone Pharmaceuticals, Inc.    
Prepaid expenses and other current assets   $ 3,000
Marketable securities   8,811,000
Accounts payable and accrued expenses   410,000
Derivative liabilities   $ 10,475,000